Report : North America Automated Cell Counters Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Type (Hemocytometer, Flow Cytometers, Electrical Impedance Coulter Counters, and Spectrophotometers) and End User (Hospitals, Research Laboratories, Diagnostics Centers, and Others)
At 6.1% CAGR, the North America Automated Cell Counters Market is speculated to be worth US$ 4,146.38 million by 2028, says Business Market Insights
According to Business Market Insights’ research, the North America automated cell counters market was valued at US$ 2,908.97 million in 2022 and is expected to reach US$ 4,146.38 million by 2028, registering an annual growth rate of 6.0% from 2022 to 2028. Prevalence of infectious and chronic diseases and increase in drug discovery activities.
Chronic diseases are conditions that are present in an individual for one or more years, require ongoing medical attention, and can also result in limited daily activities. Chronic diseases are currently the major cause of death among adults in several countries. According to World Health Organization (WHO), forty-one million people die yearly due to chronic diseases, equivalent to 71% of all deaths North America. As per the Centers for Disease Control and Prevention (CDC), six in ten adults in the US have a chronic disease, and four in ten adults have two or more chronic diseases. Infectious diseases are caused by infectious agents, including viruses, bacteria, parasites, fungi, and toxic products. HIV is a major public health issue across the North America. As per The Joint United Nations Programme on HIV/AIDS (UNAIDS), ~ 37.7 million people had HIV in 2020; out of these, 1.7 million were children aged 0–14 years, and 36 million were adults. Further, over half of them (53%) were girls and women, and 1.5 million new HIV cases were North America reported in 2020. Similarly, hepatitis is inflammation of the liver caused by a viral infection. The five primary strains of hepatitis viruses are A, B, C, D, and E. According to WHO, ~58 million people have chronic hepatitis C, and ~1.5 million new infections occur every year. According to WHO, tuberculosis (TB) is the thirteenth leading cause of death in North America and the second leading infectious disease after COVID-19. Furthermore, 1.5 million deaths were caused by TB in 2020 (including 214,000 people affected by HIV). In 2020, the WHO estimated that ten million people had TB, including 1.1 million children, 3.3 million women, and 5.6 million men. TB cases are present in all age groups and countries. Diagnostics are essential in determining the direction of any medical treatment of infectious and chronic diseases. Cell counting is one of the methods that is used for the detection of such diseases. Therefore, the rising prevalence of infectious and chronic diseases across the North America is driving the growth of the automated cell counters market. This is expected to drive the market during the forecast period.
On the contrary, lack of skilled workforce and high cost of instrument hurdles the growth of North America automated cell counters market.
- Based on type, the North America automated cell counters market is categorized into hemocytometer, flow cytometers, electrical impedance coulter counters, spectrophotometers. The spectrophotometers segment held 41.8% market share in 2022, amassing US$ 1,214.81 million. It is projected to garner US$ 1,757.67 million by 2028 to expand at 6.4% CAGR during 2022–2028.
- Based on end user, the North America automated cell counters market is categorized into hospitals, research laboratories, diagnostics centers, and others. The hospitals segment held 48.3% market share in 2022, amassing US$ 1,406.31 million. It is projected to garner US$ 2,027.42 million by 2028 to expand at 6.3% CAGR during 2022–2028.
- Based on country, the North America automated cell counters market has been categorized into the US, Canada, and Mexico. Our regional analysis states that US captured 74.2% market share in 2022. It was assessed at US$ 2,158.75 million in 2022 and is likely to hit US$ 3,119.74 million by 2028, exhibiting a CAGR of 6.3% during the forecast period.
Key players dominating the North America automated cell counters market are Eppendorf; Thermo Fisher Scientific Inc.; Countstar Inc.; Bio-Rad Laboratories, Inc.; F. Hoffman-La Roche Ltd; Chemometec A/S; ALIGNED GENETICS; Beckman Coulter, Inc. (Danaher); Nanoentek; Olympus Corporation; MERCK KGaA; Sysmex Corporation; Agilent Technologies, Inc.; Abbott; and Nexcelom Bioscience LLC. among others.
- In Dec 2020, Merck launches Scepter 3.0 for wireless cell counting.
- In June 2022, Sysmex Receives FDA Clearance for Residual White Blood Cell Counting.
Contact Person: Sameer Joshi
Phone: +1- 646- 491- 9876
Email id: firstname.lastname@example.org